Welcome to our dedicated page for Day One Biopharmaceuticals news (Ticker: DAWN), a resource for investors and traders seeking the latest updates and insights on Day One Biopharmaceuticals stock.
Day One Biopharmaceuticals was a Nasdaq-listed biopharmaceutical company focused on targeted therapies for people of all ages with life-threatening diseases. News about DAWN centered on oncology product and pipeline developments, including OJEMDA (tovorafenib), an FDA-approved medicine marketed in the U.S. for pediatric low-grade glioma, and clinical-stage assets in rare cancers.
Coverage also includes the completed acquisition by Servier, related shareholder-rights and governance notices, capital-structure updates, operating and financial results, and clinical or regulatory disclosures tied to OJEMDA and other oncology programs.
Day One (Nasdaq: DAWN) will present new long‑term data for OJEMDA (tovorafenib) from the registrational Phase 2 FIREFLY-1 trial at the 30th SNO Annual Meeting on November 23, 2025. The oral presentation reports >36‑month follow‑up in patients aged 6 months–25 years with relapsed or progressive pediatric low‑grade glioma and will include treatment‑free interval (TFI) data disclosed for the first time.
The presentation covers once‑weekly oral monotherapy after completion of a full course of 26 cycles (~24 months); an earlier data cut is in the abstract and updated results will be shown at the meeting in Honolulu.
Day One (Nasdaq: DAWN) reported third quarter 2025 results with accelerating commercial performance of OJEMDA and strengthened financial position. Q3 OJEMDA net product revenue was $38.5M, up 15% sequentially; YTD U.S. OJEMDA revenue was $102.6M, +89% versus 2024. Quarterly TRx reached 1,256 and new patient starts rose 19% sequentially. The company raised full-year 2025 OJEMDA revenue guidance to $145–$150M. R&D spend was $31.4M and SG&A $28.1M in Q3; net loss was $19.7M. Cash, cash equivalents and short-term investments totaled $451.6M as of Sep 30, 2025. Three-year FIREFLY-1 data will be presented Nov 23, 2025.
Day One Biopharmaceuticals (Nasdaq: DAWN) will report its third quarter 2025 financial results on Tuesday, November 4, 2025.
The company will host a live conference call and webcast on Nov. 4, 2025 at 4:30 p.m. ET to discuss results and corporate progress. Live audio will be available in the Events section of Day One's Media & Investors page, and an archived replay will be accessible for 30 days after the event.
Day One Biopharmaceuticals (NASDAQ:DAWN) reported strong Q2 2025 financial results, with OJEMDA net product revenue of $33.6 million, representing a 310% increase year-over-year and 10% quarter-over-quarter growth. The company provided full-year 2025 OJEMDA revenue guidance of $140-150 million.
Key highlights include OJEMDA prescriptions exceeding 1,000 in Q2 2025 (up 346% YoY), appointment of Dr. Michael Vasconcelles as Head of R&D, and continued progress in clinical trials. The company ended Q2 with $453.1 million in cash and reported a net loss of $30.3 million. R&D expenses decreased to $36.1 million from $92.1 million in Q2 2024, primarily due to prior year's MabCare license payment.
Day One Biopharmaceuticals (NASDAQ: DAWN), a company focused on developing targeted therapies for life-threatening diseases, has scheduled its Q2 2025 financial results conference call and webcast for Tuesday, August 5, 2025, at 4:30 p.m. ET.
The event will include a discussion of financial results and corporate updates. Investors can access the live webcast through Day One's Events page, and a replay will be available for 30 days following the presentation.
Day One Biopharmaceuticals (DAWN) has announced it will host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its first quarter 2025 financial results and corporate updates. The live audio webcast will be available on the company's Investors & Media page, with a replay accessible for 30 days following the event in the Events & Presentations section.
Day One Biopharmaceuticals (DAWN) reported its Q4 and full year 2024 financial results, highlighting strong performance of its flagship drug OJEMDA. The company achieved $29.0 million in Q4 OJEMDA net product revenues, a 44% increase from Q3, and $57.2 million for the full year 2024.
Since OJEMDA's launch in April 2024, over 1,600 prescriptions have been written. The drug received Exclusively Pediatric designation from CMS, reducing its Medicaid and 340B minimum rebate percentage to 17.1%. The company reported a net loss of $65.7 million for Q4 and $95.5 million for full year 2024.
R&D expenses increased to $227.7 million for 2024, primarily due to DAY301-related payments. The company maintains a strong financial position with $531.7 million in cash and equivalents as of December 31, 2024.
Day One Biopharmaceuticals (DAWN) has announced it will host a conference call and webcast on Tuesday, February 25, 2025, at 4:30 p.m. ET to discuss its fourth quarter and full-year 2024 financial results and corporate progress. The live audio webcast will be available on the company's Investors & Media page, with a replay accessible for 30 days following the event in the Events & Presentations section.